CDK4 and interstitial lung disease: Similarly, another meta-analysis investigated the incidence of ILD among patients with various types of cancer receiving the CDK4/6i abemaciclib, palbociclib, or ribociclib across 12 Phase 2/3 clinical trials (N = 16060) [32].